Dysport, the latest injectable wrinkle treatment, has finally arrived as the first true competitor to Botox. On April 29, 2009, U.S. Food and Drug Administration sanctioned Dysport for both cosmetic and therapeutic use.
Dysport is a simple, effective, non-surgical treatment that works by relaxing facial muscles, thereby reducing and smoothing away frown-lines and wrinkles. Dysport is a form of botulinum type A, similar to the protein found in Botox. Botox was developed in the US and Dysport was developed in the UK. For this reason, Dysport was used first in Europe. In Europe and South America, where both Botox and Dysport are available, Dysport is more popular.
Dysport has been available worldwide since 1991 and has been approved in the European Union, Brazil, Argentina and more than 26 countries worldwide for more than a decade. Since that time, thousands of treatments have been safely and effectively performed for a variety of conditions ranging from frown lines to axillary hyperhidrosis (excessive sweating under the armpits).
Dysport and Botox are both cosmetic injections that temporarily relax the muscles in the face that create expressions, such as frown lines between the brows, that over time result in visible facial lines and deeper creases. Dysport is similar to Botox in that the longevity of the treatments are up to 4 months and while similar, the dosing units of Dysport are not the same as and are not interchangeable with Botox . Another benefit of Dysport is the shortened length for the mechanism of action in achieving results for our patients and the reduced cost at this time compared to Botox.
Dysport vs. Botox read more at Frequently Asked Questions page.